Literature DB >> 24528060

Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features.

Mehmet Kaba1, Necip Pirincci, Erdal Benli, Ilhan Gecit, Mustafa Gunes, Mehmet Bilgehan Yuksel, Adem Tok, Ahu Sarbay Kemik.   

Abstract

BACKGROUND: Evidence indicates that Dickkopf-1 (DKK-1) levels may be a biomarker for cancer risk. The aim of this study was to assess DKK-1 and its correlation with clinic-pathological features in patients with bladder cancer.
MATERIALS AND METHODS: DKK-1 levels were determined in serum samples from 90 patients with bladder cancer before transurethral tumor resection. The concentrations of DKK-1 were determined by using enzyme linked immune-sorbent assay (ELISA).
RESULTS: Elevated preoperative DKK-1 levels were associated with tumor stage (p<0.001), grade (p<0.001) and histological grade (p<0.001).
CONCLUSIONS: The results of our study demonstrated that the level of serum DKK-1 is correlated with both disease progression and increase in the tumor grade. Preoperative serum DKK-1 elevation may thus represent a novel marker for the determination of bladder cancer and the detection of patients with a likely poor clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528060     DOI: 10.7314/apjcp.2014.15.1.381

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

Review 1.  What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Authors:  Mohamed Ismat Abdulmajed; Eyüp Burak Sancak; Berkan Reşorlu; Gydhia Zuhair Al-Chalaby
Journal:  Turk J Urol       Date:  2014-10-15

2.  Serum dickkopf-1 as a biomarker in screening gastrointestinal cancers: a systematic review and meta-analysis.

Authors:  Bin Liang; Liansheng Zhong; Qun He; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao
Journal:  Onco Targets Ther       Date:  2015-10-22       Impact factor: 4.147

Review 3.  Drug Discovery of DKK1 Inhibitors.

Authors:  Hewen Jiang; Zongkang Zhang; Yuanyuan Yu; Hang Yin Chu; Sifan Yu; Shanshan Yao; Ge Zhang; Bao-Ting Zhang
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

4.  miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro.

Authors:  Ye Lei; Xiheng Hu; Bin Li; Minyuan Peng; Shiyu Tong; Xiongbing Zu; Zhi Wang; Lin Qi; Minfeng Chen
Journal:  Med Sci Monit       Date:  2014-10-07

5.  Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases.

Authors:  Rong Qiao; Runbo Zhong; Qing Chang; Jiajun Teng; Jun Pei; Baohui Han; Tianqing Chu
Journal:  Oncotarget       Date:  2017-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.